<DOC>
	<DOCNO>NCT01356875</DOCNO>
	<brief_summary>Transfusional dependence associate closely independently low survival patient myelodysplastic syndrome ( MDS ) , especially patient low risk accord IPSS . Treatment patient hydralazine + valproic acid alternative treatment 5-azacytidine low cost possibly effective few side effect . The objective phase II study determine effectiveness combination therapy hydralazine + Ac . Valproic compare best supportive care . The investigator select 42 patient per group , 14 week treatment investigator study group hematological response ( transfusion-dependent , hemoglobin , cytogenetics morphology ) treatment safety ( adverse reaction vital sign ) 1 year start treatment . The concentration hemoglobin , number transfusion , platelet , neutrophils continuous variable group compare Student Mann-Whitney , appropriate . For comparison cytogenetic morphological response categorical variable group Chi square use . And within group investigator compare variable treatment t-test pair data Wilcoxon test .</brief_summary>
	<brief_title>Treatment Myelodysplastic Syndromes Comparing Hydralazine/Ac . Valproic Supportive Care Patients Not Candidates , Refractory and/or Intolerant Intensive Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<criteria>1 . Ability understand voluntarily sign consent form . 2 . Age â‰¥ 18 year time signing informed consent form . 3 . Ability willingness meet schedule study visit protocol requirement . 4 . Documented diagnosis SMDs accord criterion disease risk IPSS intermediate2 , high risk risk transfusion requirement . 5 . Transfusiondependent anemia erythrocyte define absence period 56 consecutive day without transfusion red blood cell least 112 day prior ( 16 week ) . 6 . Engage woman men use highly effective contraception . 7 . Patients candidate treatment azacitidine chemotherapy Patients exclusion criterion may include trial : 1 . Pregnant breastfeeding . 2 . After hematopoietic stem cell transplantation . 3 . Patients vitamin B12 deficiency , Folic Acid Iron 4 . Any severe psychiatric illness condition prevents patient sign consent form patient involve unacceptable risk case participate study . 5 . Hypersensitivity hydralazine / AC . Valproic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>Transfusion</keyword>
	<keyword>Hydralazine</keyword>
	<keyword>valproic acid</keyword>
</DOC>